Larimar Therapeutics Inc (LRMR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Larimar Therapeutics Inc (LRMR) has a cash flow conversion efficiency ratio of -0.346x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.03 Million) by net assets ($127.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LRMR market cap for the company's overall valuation and market capitalisation.
Larimar Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Larimar Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Larimar Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Larimar Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Larimar Therapeutics Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Citra Putra Realty Tbk PT
JK:CLAY
|
3.955x |
|
Bank7 Corp
NASDAQ:BSVN
|
0.064x |
|
Wuxi Acryl Technology Co Ltd
SHG:603722
|
0.005x |
|
HELLOFRESH UNSP.ADS/025
F:HFG0
|
0.203x |
|
Hoang Huy Investment Financial
VN:TCH
|
0.067x |
|
Belo Sun Mining Corp.
TO:BSX
|
-0.161x |
|
HiVi Acoustics Technology Co Ltd
SHE:002888
|
0.013x |
|
Eurocharm Holdings Co Ltd
TW:5288
|
0.027x |
Annual Cash Flow Conversion Efficiency for Larimar Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Larimar Therapeutics Inc from 2012 to 2025. View today's stock price for Larimar Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $78.08 Million | $-113.20 Million | -1.450x | -252.00% |
| 2024-12-31 | $171.81 Million | $-70.76 Million | -0.412x | -0.59% |
| 2023-12-31 | $81.72 Million | $-33.46 Million | -0.409x | -64.71% |
| 2022-12-31 | $110.90 Million | $-27.57 Million | -0.249x | +61.97% |
| 2021-12-31 | $64.41 Million | $-42.10 Million | -0.654x | -38.94% |
| 2020-12-31 | $89.69 Million | $-42.20 Million | -0.470x | -101.44% |
| 2019-12-31 | $-694.00K | $-22.70 Million | 32.707x | +6025.11% |
| 2018-12-31 | $93.27 Million | $-51.49 Million | -0.552x | +1.39% |
| 2017-12-31 | $78.22 Million | $-43.78 Million | -0.560x | -31.10% |
| 2016-12-31 | $121.73 Million | $-51.98 Million | -0.427x | -21.25% |
| 2015-12-31 | $169.11 Million | $-59.55 Million | -0.352x | -30.24% |
| 2014-12-31 | $104.44 Million | $-28.24 Million | -0.270x | +36.52% |
| 2013-12-31 | $35.22 Million | $-15.00 Million | -0.426x | +74.75% |
| 2012-12-31 | $8.06 Million | $-13.59 Million | -1.687x | -- |
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.